Sanofi Offers to Acquire Kiadis for €308 Million
The Kiadis board believes that Sanofi will provide financial and resource support to facilitate the Kiadis NK-cell medicines’ development.Global biopharmaceutical company Sanofi SA (NASDAQ: SNY) has offered to acquire cell-based immunotherapy company Kiadis. The acquisition offer was revealed in a press release by Sanofi on the 2nd of November. Sanofi Offers to Buy
Read More